Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
This browser is no longer supported.
To provide you with the best possible experience, we kindly ask you to switch to a supported browser:
In this day and age, it’s important to be informed as to the environmental impact of the treatments we prescribe our patients.
That’s why we’re proud to say that, compared with other asthma devices, Relvar Ellipta has one of the lowest carbon footprints.1
This graph has been independently created by GSK from the original data. The same results were first published in Janson C, et al. Thorax 2020;75:82–84.
From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.
*If using on average two doses per day.
CO2e, annual carbon footprint; MDI, metered dose inhaler.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210006